Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: Evaluation by 24‐hour ambulatory blood pressure monitoring

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood pressure. Supplement

• Publication date

  2005-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/08038020510040621PMID 16060411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure.

  2004cited by this paper
• Combination Calcium Channel Blocker Therapy in the Treatment of Hypertension

  2001cited by this paper
• A Smooth Blood Pressure Control is obtained over 24 h by Delapril in Mild to Moderate Essential Hypertensives

  2001cited by this paper
• The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment

  2001cited by this paper
• Efficacy, Tolerability, and Impact on Quality of Life of Long-Term Treatment with Manidipine or Amlodipine in Patients with Essential Hypertension

  2001cited by this paper
• Low-dose combination therapy: the rationalization for an ACE inhibitor and a calcium channel blocker in higher risk patients.

  2001cited by this paper
• Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients.

  2000cited by this paper
• Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy

  2000cited by this paper
• Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society

  2000cited by this paper
• [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension].

  2000cited by this paper
• Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan.

  2000cited by this paper
• Guidelines for the management of hypertension.

  2000cited by this paper
• Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy

  2000cited by this paper
• Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension

  2000cited by this paper
• Contribution of fixed low-dose combinations to initial therapy in hypertension

  1999cited by this paper
• 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

  1999cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study.

  1998cited by this paper
• Prevalence, treatment, and control of hypertension in the French population: data from a survey on high blood pressure in general practice, 1994.

  1998cited by this paper
• The smoothness index: A new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension

  1998cited by this paper
• Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.

  1998cited by this paper
• Effects of an ACE inhibitor and a calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild to moderate hypertension.

  1998cited by this paper
• Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM

  1998cited by this paper
• The trough:peak ratio and the smoothness index in the evaluation of control of 24 h blood pressure by treatment in hypertension.

  1998cited by this paper
• Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

  1997cited by this paper
• Assessment of antihypertensive treatment by ambulatory blood pressure

  1997cited by this paper
• Heart rate and the cardiovascular risk

  1997cited by this paper
• Combination antihypertensive therapy: does it have a role in rational therapy?

  1997cited by this paper
• Fixed low-dose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension.

  1997cited by this paper
• Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure.

  1997cited by this paper
• Comparison of different fixed antihypertensive combination drugs: a double‐blind, placebo‐controlled parallel group study

  1997cited by this paper
• Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study.

  1996cited by this paper
• Reversing endothelial dysfunction with ACE inhibitors. A new trend.

  1996cited by this paper
• Beyond trough:peak ratio: a new index of the smoothness of the antihypertensive effect of a drug

  1996cited by this paper
• Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor.

  1995cited by this paper
• Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base.

  1995cited by this paper
• Lack of placebo effect on ambulatory blood pressure.

  1995cited by this paper
• Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects

  1995influential reference
• Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991.

  1995cited by this paper
• The physiologic relevance of smooth twenty-four-hour blood pressure control.

  1994cited by this paper
• Trough: peak ratio the rationale behind the United States Food and Drug Administration recommendations

  1994cited by this paper
• Trough: peak ratio

  1994cited by this paper
• Prognostic value of 24-hour blood pressure variability

  1993cited by this paper
• Efficacy and mode of action of manidipine: a new calcium antagonist.

  1993cited by this paper
• 1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.

  1993cited by this paper
• Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

  1993cited by this paper
• Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo

  1993cited by this paper
• Ambulatory blood pressure monitoring in the design of antihypertensive drug trials.

  1991cited by this paper
• Calcium antagonists as anti-atherosclerotic agents.

  1990cited by this paper
• Heart rate and cardiovascular mortality: the Framingham Study.

  1987cited by this paper

• Influence of intelligent management mode based on Internet of Things on self-management ability and prognosis of elderly patients with hypertensive heart disease: An observational study

  2024cites this paper
• Stability-indicating micellar electrokinetic chromatography technique for simultaneous measurement of delapril and manidipine from a combination drug formulation.

  2014cites this paper
• Chemistry and Biochemistry of Terpenoids from Curcuma and Related Species

  2013cites this paper
• Benefits of delapril in hypertensive patients along the cardiovascular continuum

  2013cites this paper
• Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence

  2012cites this paper
• Delapril/Manidipine

  2012cites this paper
• Combination Delapril/Manidipine as Antihypertensive Therapy in High-Risk Patients

  2011cites this paper
• Delapril and Manidipine Measurements by Liquid Chromatography—Tandem Mass Spectrometry in a Pharmaceutical Formulation

  2011cites this paper
• Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk

  2008cites this paper
• Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus

  2008cites this paper
• Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage

  2007cites this paper
• Delapril plus Indapamide

  2007cites this paper
• Manidipine-delapril combination in the management of hypertension.

  2007cites this paper
• Manidipine–delapril combination in the management of hypertension

  2007cites this paper
• Fixed-drug combinations as first-line treatment for hypertension.

  2006cites this paper
• Clinical utility and applicability of smoothness index, normalized smoothness index and individualized RDH index during treatment of essential hypertension

  2006cites this paper
• Hypertension control – A global challenge

  2005cites this paper
• Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a phase III, multicenter, open-label, clinical trial.

  2003cites this paper